November Monthly Price Drop: ₹80,000 all-inclusive until 16 November, 11:59 PM IST. 52% off.|Foresight ₹1,40,000 ₹67,797 + 18% GST|12 months of accessGet Foresight
All board jobs

Applications closed

This seat is no longer taking applications — closed on 18 September 2026.

The brief stays here for reference. Seats like it open every week.

See live board seats
India ID ExchangeAudit Committee Chair & Financial Expert

Independent Director — Diagnostic Services | Clinical Quality, Audit and Network Integrity

Confidential listed diagnostic-services network Gurugram· Healthcare & Diagnostic Services
AuditClinical QualityRisk

Closed 18 September 2026

Company: Confidential listed diagnostic-services network
Board base: Gurugram, Haryana
Sector: Pathology, radiology and preventive diagnostics
Appointment: Independent Director, Non-Executive
Intended committees: Audit Committee; Clinical Quality & Patient Trust Committee
Time commitment: 26–32 days annually, including Board preparation, laboratory visits and quality reviews
Application deadline: 18 September 2026
Expected appointment: November 2026

Company context

The company operates a national network of reference laboratories, regional processing hubs, hospital laboratories and patient-facing collection centres. It processes routine and specialised pathology, molecular, genetic and radiology tests for individual patients, hospitals, clinicians, insurers and corporate health programmes. Growth is being pursued through owned laboratories, franchise collection centres, hospital partnerships, home collection and selective acquisitions.

The Board is strengthening independent oversight as the company moves from a founder-led diagnostic chain toward an institution whose clinical data, quality systems and acquisition discipline can withstand public-market scrutiny.

Market hint: A large northern India base, hub-and-spoke laboratory network, hospital contracts, home collection and a growing molecular-testing portfolio may suggest several listed or IPO-scale diagnostic groups. No brand, promoter, laboratory count or acquisition is identified.

Board mandate

The director will connect clinical reliability, revenue quality, patient trust and capital allocation. The role is not to interpret individual test results or direct medical practice. It is to ensure that every reported result is supported by validated methods, traceable samples, competent personnel, controlled systems and honest disclosure.

Strategic priorities

  1. Establish Board visibility from patient order through collection, transport, accession, testing, validation, reporting, amendment and storage; identify where identity, temperature, timing or manual intervention can compromise a result.
  2. Govern test-menu additions through clinical utility, method validation, equipment capability, reference ranges, quality control, demand evidence and reimbursement—not marketing novelty.
  3. Create a network quality dashboard covering sample rejection, recollection, turnaround distribution, critical-result notification, amended reports, external-quality performance, complaints and repeat failures by laboratory and franchise.
  4. Review hospital-laboratory contracts for minimum volume, pricing, staffing, equipment, working capital, service levels, data access and termination exposure; separate strategic contracts from loss-making volume.
  5. Challenge referral, doctor-engagement, health-package and corporate-channel incentives for conflicts, unnecessary testing, misleading discounts and customer-acquisition economics.
  6. Protect genomic, pathology and health data through consent, access, retention, secondary use, model training, breach response and patient correction rights.
  7. Require acquisition diligence on licences, method validation, quality events, cash collections, related parties, equipment, pathologist dependence, patient data and integration capacity.
  8. Review revenue cut-off, unbilled hospital work, franchise settlement, package breakage, doubtful receivables, reagent inventory and equipment-capitalisation with the statutory and internal auditors.
  9. Build succession for pathologists, laboratory directors, quality leaders, molecular scientists and regional operations rather than relying on a small founder-clinician group.

Decisions expected at Board level

  • Whether a fast-growing specialised test should scale before external-quality and clinical-utility evidence mature.
  • Whether to renew a high-volume hospital contract that dilutes margin and creates receivable concentration.
  • Whether an acquired laboratory may retain its brand and methods after material quality differences are identified.
  • Whether an amended-report cluster requires patient notification, clinician outreach or regulator escalation.
  • Whether AI-assisted interpretation can enter clinical workflow while preserving attributable specialist judgement.

Candidate profile

Essential: Former diagnostic, hospital, healthcare-services, medical-technology or regulated laboratory CEO, COO, CFO, quality leader, clinician-executive or healthcare regulator; listed-company Board or Audit Committee experience; direct accountability for clinical-quality, financial-control or network-integration decisions; ability to challenge eminent clinicians and commercial leaders without entering individual diagnosis.

Preferred: pathology or radiology network experience; molecular/genetic testing; healthcare data and cyber governance; post-acquisition clinical integration; Audit Committee chair capability.

Eligibility and conflicts

Active IICA Independent Directors Databank inclusion is mandatory, with the applicable proficiency-test requirement completed or a valid exemption documented. All statutory independence, DIN, KYC, disqualification, tenure, directorship and committee-capacity conditions must be satisfied.

Candidates must disclose relationships with hospital groups, doctors, referring organisations, insurers, laboratory franchises, reagent and equipment vendors, genetic-testing companies, auditors, acquisition targets and competing networks.

First-year outcomes

  • One verified network quality system with escalation thresholds and accountable closure.
  • Audit visibility over hospital contracts, channel economics, receivables and reagent inventory.
  • Board-approved governance for clinical AI, genomic data and report amendments.
  • Acquisition gates that protect quality and cash before expansion proceeds.
  • Reduced reliance on founder-clinicians through credible clinical and quality succession.

New to Pharma & Healthcare boards?

What these boards look for, how the committees are composed, what the seats pay, and the eligibility rules that apply.

Seats like this, open now

India ID ExchangeLong Term

Audit Committee Chair — Communications Infrastructure, Customer Trust and Technology Risk

Confidential listed communications-services company Delhi NCR· Communications Infrastructure and Services
Upcoming Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditRiskNRC

The Audit Committee Chair must understand how capital, customer usage, service availability, partner settlements, billing, spectrum or licence obligations, technology assets and cyber risk combine in the financial result. The Board does not need an engineer who approves network design; it needs a…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 41d 17:39:06· 27 December 2026 at 11:59 pm IST
Posted 23 OctApply
India ID ExchangeLong Term

Stakeholders Relationship Committee Chair — Trust, Disclosure and Digital Service Accountability

Confidential listed technology-services company Mumbai· Technology Services
Upcoming Foresight Priority PeriodGeneral Independent Director First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →StakeholdersCSR

The Board seeks a director to chair Stakeholders Relationship and contribute to CSR. The formal duties—shareholder servicing, transfers, dematerialisation, grievances and compliance—remain essential. The opportunity is to turn recurring questions, delayed resolution and communication gaps into…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 38d 17:39:06· 24 December 2026 at 11:59 pm IST
Posted 22 OctApply
India ID ExchangeLong Term

Independent Director — Audit, NRC and Risk in Advanced Industrial Manufacturing

Confidential listed industrial manufacturing company Vadodara· Advanced Industrial Manufacturing
Upcoming Foresight Priority PeriodGeneral Independent DirectorAuditNRCRisk

The appointee will serve on Audit, NRC and Risk without being recruited to dominate any of them. The Board is looking for a director who can bring independent synthesis: listen to specialists, identify the assumption that connects their reports, and ask the question that changes a decision. Strong…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 43d 17:39:06· 29 December 2026 at 11:59 pm IST
Posted 20 OctApply
India ID ExchangeLong Term

Audit Committee Chair and Risk Member — Listed Investment and Financial Services Company

Confidential listed investment and financial services company Mumbai· Investment and Financial Services
Upcoming Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditRisk

The Audit Committee Chair will apply three tests to every material issue. Is the number supported? Is the customer or investor treated fairly? Is the control robust when markets and behaviour change? A favourable answer to only one or two is not sufficient in a business that manages money,…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 34d 17:39:06· 20 December 2026 at 11:59 pm IST
Posted 19 OctApply